Discover 3,059 paid clinical trials in Brockton, Massachusetts. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Filter
2
Filter results
Results: 3,059
Pulmonary Care and Research Collaborative Patient Registry
for
Interstitial Lung Disease
Location: Boston MA
Sponsor: Pulmonary Care and Research Collaborative Limited
Sex: All
Age: 18+
Code: NCT05445817
Recruiting
A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer
for
Breast Cancer
Location: Boston MA, East Patchogue NY, The Bronx NY,
Sponsor: Genentech, Inc.
Sex: All
Age: 18+
Code: NCT07100106
Phase 1, Phase 2, Recruiting
Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer
for
Ovarian Cancer, Fallopian Tube Cancer,
Location: Boston MA, Greenfield Park, Montreal, Quebec, Toronto,
Sponsor: Regeneron Pharmaceuticals
Sex: Female
Age: 18+
Code: NCT06787612
Phase 2, Recruiting
Treating Insomnia in Mild Cognitive Impairment
for
Mild Cognitive Impairment (MCI), Insomnia,
Location: Boston MA
Sponsor: Beth Israel Deaconess Medical Center
Sex: All
Age: 60+
Code: NCT06687161
Recruiting
Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an IDH1 Mutation
A Trial of Setmelanotide in Patients With Congenital Hypothalamic Obesity (Sub-study of NCT05774756)
for
Hypothalamic Obesity,
Location: Boston MA, New York NY, Philadelphia PA, Chicago IL,
Sponsor: Rhythm Pharmaceuticals, Inc.
Sex: All
Age: 4+
Code: NCT06760546
Phase 3, Recruiting
Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)
for
Breast Cancer, Triple Negative Breast Cancer, Residual Cancer,
Location: Boston MA, Philadelphia PA, Nashville TN,
Sponsor: Dana-Farber Cancer Institute
Sex: All
Age: 18+
Code: NCT04434040
Phase 2, Recruiting
Supportive Psychoeducational Intervention for Patients With Brain Tumors (Acceptance and Commitment Therapy-based Supportive Intervention for Patients With Central Nervous System Tumors)
for
Malignant Brain Tumor, Glioma, Coping Skills,
Location: Boston MA
Sponsor: Massachusetts General Hospital
Sex: All
Age: 18+
Code: NCT06099743
Recruiting
Use of Indocyanine Green (ICG) for the Diagnosis of Biliary Atresia
for
Biliary Atresia
Location: Boston MA
Sponsor: Boston Children's Hospital
Sex: All
Age: 0
Code: NCT07513038
Phase 1, Phase 2, Recruiting
Phase 3 Trial of eRapa in Patients With Familial Adenomatous Polyposis
for
Familial Adenomatous Polyposis (FAP)
Location: Boston MA, New Haven CT, Danville PA, Baltimore MD,
Sponsor: Rapamycin Holdings Inc.
Sex: All
Age: 18+
Code: NCT06950385
Phase 3, Recruiting
Assessing the Safety, Tolerability, and Efficacy of APR-2020 in Pediatric and Adolescent Subjects With RPS19 Deficient Diamond-Blackfan Anemia
for
RPS19 Deficient Diamond-Blackfan Anemia
Location: Boston MA, Stanford CA
Sponsor: Apriligen, Inc.
Sex: All
Age: 2 - 25
Code: NCT07476183
Phase 1, Recruiting
AERA Pediatrics Registry
for
Dysfunction of Eustachian Tube
Location: Boston MA, Philadelphia PA, West Bloomfield MI,
Sponsor: Integra LifeSciences Corporation
Sex: All
Age: 0 - 18
Code: NCT07071298
Recruiting
Bowel Continence Across the Lifespan in People With Spina Bifida
Location: Boston MA, Philadelphia PA, Washington D.C. DC,
Sponsor: David Chu
Sex: All
Age: 5+
Code: NCT07390318
Recruiting
Radiation Free Study
for
Aortic Aneurysm
Location: Worcester MA, Philadelphia PA, Birmingham AL, Dallas TX
Sponsor: Philips Clinical & Medical Affairs Global
Sex: All
Age: 18+
Code: NCT06549348
Recruiting
A Study of Enlicitide Decanoate (MK-0616, an Oral PCSK9 Inhibitor) in Children and Adolescents With Heterozygous Familial Hypercholesterolemia (MK-0616-029)
for
Heterozygous Familial Hypercholesterolemia (HeFH)
Location: Boston MA, Wilmington DE, Washington D.C. DC,
Sponsor: Merck Sharp & Dohme LLC
Sex: All
Age: 6 - 17
Code: NCT07058077
Phase 2, Phase 3, Recruiting
Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer